NCT04697446View on ClinicalTrials.gov

External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC

UnknownOBSERVATIONAL
Enrollment

279

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

October 31, 2021

Study Completion Date

October 31, 2021

Conditions
RET-fusion Non Small Cell Lung CancerLung NeoplasmCarcinoma, Non-Small-Cell LungRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract DiseasesCarcinoma, BronchogenicBronchial DiseasesHead and Neck NeoplasmsCarcinomaNeoplasms by Histologic TypeNeoplasms, Germ Cell and EmbryonalNeoplasms, Nerve TissueMetastatic Non Small Cell Lung Cancer
Trial Locations (3)

6000

Lucerne Cantonal Hospital, Lucerne

10065

Memorial Sloan Kettering Cancer Center, New York

31300

University Hospital Center of Toulouse - Larrey Hospital, Toulouse

Sponsors

Collaborators (1)

Analysis Group, Inc.
All Listed Sponsors
collaborator

Analysis Group, Inc.

INDUSTRY

lead

Blueprint Medicines Corporation

INDUSTRY

NCT04697446 - External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC | Biotech Hunter | Biotech Hunter